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ABSTRACT
Introduction: The World Health Organization 
(WHO) recommends universal infant hepatitis B 
virus (HBV) vaccination as the most effective pre-
ventive measure against HBV-induced disease in 
endemic areas. More than 160 countries have fol-
lowed the WHO recommendations to incorporate 
HBV vaccination in their national infant immu-
nization programs. While antibodies to hepa- 
titis B surface antigen (anti-HBs) concentrations 
progressively decrease following vaccination in 
infancy, protection persists, probably due to last-
ing immune memory. Hence, it is thought that 
future exposure to wild-type virus or HBV vac-
cine will induce a protective secondary immune 
response. Methods: Children aged 7-8 years old 
0005-x
1
who had been vaccinated in infancy with a hex-
avalent DTacP-IPV-HB-Hib vaccine (Hexavac®; 
Sanofi Pasteur MSD, Lyon, France) and chil-
dren aged 7-9 years vaccinated in infancy with a 
DT-HB vaccine (Primavax®; Sanofi Pasteur MSD), 
whose anti-HBs concentrations had fallen below 
the seroprotective threshold of 10 mIU/mL at 
age 4.5-6 years, received a challenge dose of 
monovalent HBV vaccine (HBVAXPRO®; Sanofi 
Pasteur MSD) to assess persistence of protection. 
Results: One month postchallenge, 54 of 61 
(88.5%) Hexavac-primed seronegative children 
and 34 of 40 (85.0%) Primavax-primed sero- 
negative children had anti-HBs concentrations 
≥10 mIU/mL. The percentage of protected child- 
ren would have been even higher if the children 
who still had protective antibody levels (who 
were not included in this challenge study) had 
been assessed (42.1% with Hexavac, 55.4% with 
Primavax). Conclusion: Vaccination with a HBV-
containing multivalent vaccine during infancy 
induces a lasting immune memory that can be 
boosted, even in children with a decline in anti-
HBs concentrations. The present results confirm 
that the full primary vaccination schedule in 
infancy seems to confer long-term protection via 
immune memory and that an additional HBV 
dose is not generally required.
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INTRODUCTION
Hepatitis B virus (HBV) is a major global pub-
lic health problem. More than 350 million of 
the 2 billion people infected worldwide have 
chronic HBV infections and are at serious risk of 
developing cirrhosis and liver cancer.1 Safe and 
effective vaccines exist and the World Health 
Organization (WHO) recommends universal 
infant HBV vaccination as the most effective 
preventive measure against HBV-induced disease 
in endemic areas. More than 160 countries have 
followed the WHO recommendations to incor-
porate HBV vaccination in their national infant 
immunization programs.2 However, to be fully 
effective, the protection provided by vaccination 
in infancy needs to last until adolescence and 
early adulthood when exposure to HBV and risk 
of infection once again increases with the onset 
of sexual activity and high-risk behaviors such as 
intravenous drug abuse.3
A decrease in titers of antibodies to hepa- 
titis B surface antigen (anti-HBs) over time fol-
lowing HBV vaccination has been documented.4-7 
Despite this, there is currently no evidence to rec-
ommend the routine use of boosters in children or 
adolescents provided that they have received and 
responded to a full, three-dose, primary course 
(ie, an anti-HBs concentration ≥10 mIU/mL 
1 month after the third dose, which is consid-
ered seroprotective).7-10 Children whose anti-HBs 
concentrations fall below 10 mIU/mL are still 
considered protected against symptomatic HBV 
infection and chronic carriage for up to 15 years 
as a result of their initial seroconversion and 
subsequent immune memory.4,5,11,12
The mechanism for the persistence of protec-
tion beyond the waning of detectable antibody 
concentrations against HBV is not fully under-
stood. In addition, there is no good marker of 
persistent protection in the absence of antibody 
persistence. HBV vaccine efficacy trials have dem-
onstrated an association between initial postvac-
cination anti-HBs concentrations ≥10 mIU/mL 
and protection against clinically significant 
breakthrough HBV infection and chronic carr- 
iage. When an individual, who has previously 
been seropositive, is exposed to HBV, a rapid act- 
ivation of specific memory T and B  lymphocytes 
should occur, and a significant and clinically 
protective increase in anti-HBs concentrations 
should be observed within 5-10 days. This rapid 
secondary immune response contrasts with the 
4-12-week incubation period of HBV, and thus 
contributes to protection prior to the develop-
ment of significant HBV viremia.13,14
Only a few studies have examined anti-HBs 
persistence and most of these were carried out 
in areas of high endemicity.4,5,15-17 Furthermore, 
much of the data on long-term protection 
against HBV infection were initiated with 
plasma-derived or recombinant monovalent 
HBV vaccines rather than the combination vac-
cines containing recombinant hepatitis B sur-
face antigen (HBsAg) that have been developed 
in recent years.18-24 The extent of long-term pro-
tection against HBV infection in low-risk infants 
vaccinated from birth is not as well documented 
as that for infants in high endemicity areas, 
although protection clearly persists beyond the 
waning of detectable antibody.
MATERIALS AND METHODS
In two separate studies we examined long-
term anti-HBs persistence and immune mem-
ory to HBV in children aged between 7 and 
9 years of age who were resident in areas of low 
(France) or low to intermediate (Italy) ende-
micity and who had responded to vaccination 
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(anti-HBsAb ≥10 mIU/mL) in infancy after a 
primary series of a combination vaccine con-
taining a HBV component—either DTacP-IPV-
HB-Hib (Hexavac®; Sanofi Pasteur MSD, Lyon, 
France) or DT-HB (Primavax®, Sanofi Pasteur 
MSD) and whose antibody concentrations 
had fallen below 10 mIU/mL between 4.5 and 
6 years of age. In both studies, the children were 
challenged with a single injection of HBV vac-
cine (HBVAXPRO®; Sanofi Pasteur MSD) to sim-
ulate exposure to wild-type HBV infection, and 
postchallenge anti-HBs levels were measured to 
determine the characteristics of the anamnestic 
immune response.
Design of the Studies
The two study protocols were approved by 
the relevant ethics committees, and the stud-
ies were conducted in accordance with the 
International Conference on Harmonization 
(ICH) Good Clinical Practice (GCP) (ICH 
Topic E6 Note for Guidance on Good Clinical 
Practice CPMP/ICH/135/95) and the relevant 
national laws and regulations. Informed con-
sent forms signed by the child’s parents or legal 
guardian were required for participation in the 
study. In France, the child’s agreement to part- 
icipate was also required.
Hexavac-Primed Children
An open-label, multicenter, single-arm study 
was performed at 24 centers in France. Eligible 
children (aged 7-8 years old) had previously par-
ticipated in a phase 3 study investigating the 
safety and immunogenicity of a three-dose pri-
mary series and booster of Hexavac (containing 
5 µg of HBsAg) at 2, 3, 4, and 15-17 months or 
2, 4, 6, and 15-17 months, and had an anti-HBs 
concentration <10 mIU/mL during a subsequent 
antibody persistence study at 5.5-6 years of age 
(Figure 1).
Primavax-Primed Children
An open-label, single center, single-arm 
study was performed in Italy. Eligible children 
(aged 7-9 years old) had previously participated 
in a phase 3 study investigating the safety and 
immunogenicity of three doses of Primavax (con-
taining 5 µg of HBsAg) at 2, 4, and 11 months or 
3, 5, and 11 months, and had an anti-HBs con-
centration <10 mIU/mL in a subsequent anti-
body persistence study at 4.5-5.5 years of age 
(Figure 1).
Exclusion Criteria
In both studies children were excluded if they 
had a vaccination scheduled during the course 
of the study; if they were receiving treatment 
likely to alter the immune response (adminis-
tration of immunoglobulin, long-term systemic 
corticosteroids, or blood products); if they had 
been vaccinated against HBV since the end of 
the antibody persistence study; or if they were 
allergic to one or more of the vaccine comp- 
onents. Children were also ineligible to partic-
ipate in the studies if they: had a known his-
tory of thrombocytopenia or any coagulation 
disorder that would contraindicate intramusc- 
ular injection; had any medical condition that, 
in the opinion of the investigator, might inter-
fere with the evaluation of the study objectives; 
or were participating in another clinical study 
scheduled during the course of the study.
Study Procedures
In both studies, the subjects attended three 
visits and they were followed for up to 37 days. A 
challenge dose of HBV vaccine was administered 
at visit 1 (day 1). No blood sample was taken 
on day 1; the baseline anti-HBs concentration 
was taken to be <10 mIU/mL, from the antibody 
persistence study. Blood samples were taken at 
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visit 2 (days 7-10) and visit 3 (days 30-37). Safety 
parameters were assessed at visit 1 and visit 3.
Study Vaccine
A single, 0.5 mL dose of monovalent 
HBVAXPRO® vaccine containing 5 µg recom-
binant HBsAg was administered by intramusc-
ular injection into the deltoid muscle at visit 1.
Antibody Measurements
All antibody measurements were performed 
at Merck Research Laboratories (Wayne, PA, 
USA). Anti-HBs concentrations were measured 
by a solid-phase sandwich radioimmunoassay 
technique, using quantitative AUSAB® ABBOTT 
test kits with a detection limit of 0.06 mIU/mL 
(Abbott Laboratories North, Chicago, IL, USA). 
The counts per minute of the sample were com-
pared with the mean counts per minute from 
a group of negative control sera, and anti-HBs 
concentrations expressed as mIU/mL calculated 
as previously recommended.25
Immunogenicity Endpoints
The primary immunogenicity endpoint 
in both studies was the seroprotection rate 
defined as the percentage of tested subjects 
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with an anti-HBs titer ≥10 mIU/mL 1 month 
after administration of the challenge dose. The 
secondary immunogenicity endpoints were 
the seroprotection rate 1 week after adminis-
tration of the challenge dose, and the 1-week 
and 1-month postchallenge geometric mean 
concentrations (GMCs).
Safety Assessment
Diary cards were given to the parents or 
legal guardian to record specific adverse events. 
Solicited injection-site reactions (redness, indur- 
ation, and swelling) and other spontaneously 
reported reactions were recorded on the diary 
card for 3 days following vaccination or at any 
time between the study visits if they led to a 
medical consultation. All injection-site reactions 
≥2 cm were reported by the investigator. Fever 
(equivalent rectal temperature ≥38.0°C) and 
other spontaneously reported systemic events 
were recorded in the same manner.
Statistical Methods
Statistical analyses were performed using 
Statistical Analysis System® (SAS, version 8.2; 
SAS Inc., Cary, NC, USA). Three sets of sub-
jects were defined: the safety analysis set con-
sisted of all children who received the study 
challenge vaccine; the full analysis set (FAS) 
consisted of all children whose anti-HBs con-
centration was ≥10 mIU/mL at completion of 
the initial study, who received the study chal-
lenge vaccine, and for whom at least one post-
dose immunogenicity evaluation was available; 
the per-protocol set (PPS) was defined as those 
participating in the study without protocol 
violations that could have interfered with the 
immunogenicity evaluation.
Descriptive statistics (mean, standard devia-
tion, minimum, median, and maximum) were 
calculated for quantitative variables, and were 
used to display qualitative variables. GMCs were 
calculated for anti-HBs concentrations, and with-
in-group 95% confidence intervals (CIs) were cal-
culated for response rates and GMCs. The 95% 
CIs for response rates were based on the one- 
sample Wilson score method and those for GMCs 
were based on Student’s t distribution after log10 
transformation of individual concentrations. 
A further analysis was performed, according to 
the level of the subjects’ responses in the initial 
study with the primary series plus booster.
RESULTS
Hexavac-Primed Children
Of 106 eligible children, 95 were screened 
for inclusion in the study and 71 children were 
included (parents or legal guardian gave con-
sent) and completed the study. One of these 
children, who received the vaccine, had an anti-
HBs concentration ≥10 mIU/mL in the antibody 
persistence study and was excluded from the 
immunogenicity analyses; no blood samples 
were taken and the child was followed for safety 
only. Four children were excluded from the FAS 
and the PPS because their anti-HBs concentra-
tions were either unknown (n=1) or <10 mIU/mL 
(n=3) at the end of the initial Hexavac study. 
The FAS therefore consisted of 66 children. A 
further five children were excluded from the 
PPS because their blood samples were taken out-
side the 30-37-day window after visit 1; the PPS 
therefore consisted of 61 children (Figure 1).
The demographic and baseline characteristics 
were similar for the PPS and the FAS (FAS data in 
Table 1). The recorded medical histories and the 
previous or concomitant medications were not 
judged likely to interfere with the conduct of 
the study. No concomitant, nonstudy vaccines 
were administered.
Adv Ther (2010) 27(1):28-38. 33
Immunogenicity
One month after the challenge dose, 54 chil-
dren (88.5%) in the PPS had anti-HBs concen-
trations ≥10 mIU/mL (Table 2). The results for 
the FAS were similar to those for the PPS, with 
89.4% of children achieving seroprotective anti-
HBs concentrations. At 7 days after the challenge 
dose, 34 (55.7%) children in the PPS were sero-
protected (Table 2). The anti-HBs GMC increased 
from 9.5 mIU/mL at 7 days after the challenge 
dose to 170.3 mIU/mL at 1 month postchallenge 
dose (Table 2).
Results from a further analysis according to 
children’s antibody levels 1 month after the 
completion of the primary vaccination series 
and booster dose are shown in Table 3. Six of 
the seven nonresponders to the challenge dose 
after 1 month had an anti-HBs concentration 
between 10 and 100 mIU/mL after the primary 
immunization, while the seventh had an anti-
HBs concentration of 285 mIU/mL. It was also 
noted that two of the three subjects consid-
ered as nonresponders after the primary course 
of vaccination had anti-HBs concentrations 
≥10 mIU/ mL after the challenge dose (16 and 
1045 mIU/mL, respectively).
Safety
Safety was evaluated for all 71 children who 
received the challenge dose of vaccine. At least 
one adverse event was experienced by 22 of 
these children (31.0%), and a total of 37 adverse 
events were reported. Nine children (12.7%) 
experienced an injection-site reaction, and a 
total of 13 injection-site reactions (mostly mild 
in intensity) were reported. At least one sys-
temic adverse event was reported for 14 chil-
dren (19.7%), and a total of 24 systemic adverse 
events were reported. Five of these were assessed 
as being related to the vaccination and 19 as 
being unrelated. All adverse events unrelated 
to the vaccination were clearly related to inter-
current diseases (mostly respiratory tract infec-
tions, which were not unexpected in the study 
Table 1. Baseline demographic characteristics for the 








Mean age, years (SD) 7.7 (0.1) 7.9 (0.4)
Male sex, n (%) 27 (40.9) 22 (55.0)
Mean weight, kg (SD) 26.7 (4.2) 30.8 (6.1)
Normal physical  
examination, n (%)
64 (97.0) 40 (100)
Table 2. Geometric mean concentrations (GMCs) and seroprotection rates after challenge dose for Hexavac-primed children 




GMC (95% CI) Median (min-max) n (%) (95% CI)
Hexavac-primed children (n=61)
Time after challenge
 1 week (days 7-10) 9.5 (4.5-20.1) 12.0 (0.3-4203.0) 34 (55.7) (43.3-67.5)
 1 month (days 30-37) 170.3 (90.4-320.6) 260.0 (0.3-8171.0) 54 (88.5) (78.2-94.3)
Primavax-primed children (n=40)
Time after challenge
 1 week (days 7-10) 2.5 (1.3-5.0) 3.0 (0.3-137.0) 13 (32.5) (20.1-48.0)
 1 month (days 30-37) 107.9 (45.3-257.1) 236.5 (0.3-8898.0) 34 (85.0) (70.9-92.9)
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population). No serious or significant adverse 
events were observed during the study.
Primavax-Primed Children
Of 48 subjects who were eligible for inclusion 
in the study, 42 were enrolled. Two children were 
not vaccinated and withdrew prematurely from 
the study. The remaining 40 children completed 
the study according to the protocol, and there-
fore were included in the FAS, the PPS, and the 
safety data set. The baseline demographic details 
of the FAS are summarized in Table 1.
Immunogenicity
One month after the challenge dose of 
HBsAg, 34 (85.0%) of the children had anti-HBs 
concentrations ≥10 mIU/mL, and 7 days post- 
challenge dose 13 (32.5%) children had anti-
HBs concentrations ≥10 mIU/mL (Table 2). The 
anti-HBs GMC was 2.5 mIU/mL 7 days after the 
challenge dose and increased to 107.9 mIU/mL 
at 1 month (Table 2). Results from a further 
analysis according to children’s antibody levels 
1 month after the completion of the primary 
vaccination series and booster dose are shown 
in Table 3.
Safety
Eight of the 40 children (20%) experienced at 
least one adverse event, and a total of 11 adverse 
events were reported. Two children (5%) had one 
mild injection-site reaction each. At least one 
systemic adverse event was reported in six chil-
dren (15%) and a total of nine systemic adverse 
events were reported, of which three (moderate 
fever) were assessed as related to vaccination. 
Adverse events unrelated to the vaccination were 
clearly related to intercurrent diseases (mostly 
respiratory tract infections). No serious adverse 
events were reported during the study.
DISCUSSION
It is thought that subjects who respond to 
HBV vaccination (ie, anti-HBs concentration 
≥10 mIU/mL at any time), even if their anti-
HBs concentrations fall below 10 mIU/mL, 
will be protected against severe acute symp-
tomatic or chronic HBV disease through an 
Table 3. One-month postchallenge dose immune response according to anti-HBs titers at the end of the initial study; per-
protocol set (PPS) for Hexavac-primed children and full analysis set/PPS for Primavax-primed children.
Postbooster concentration in initial study n
ConcentrationPC (mIU/mL) SPR
GMC Median Min; max n (%)
Hexavac-primed
10 mIU/mL ≥ concentrationS1 <100 mIU/mL 9 3.5 7.0 0.3; 45.0 3 (33%)
100 mIU/mL ≥ concentrationS1 <1000 mIU/mL 24 158.2 205.0 0.3; 3709.0 23 (96%)
ConcentrationS1 ≥1000 mIU/mL 28 630.0 626.0 32.0; 8171.0 28 (100%)
Primavax-primed
10 mIU/mL ≥ concentrationS1 <100 mIU/mL 5 1.3 0.3 0.3; 16.0 2 (40%)
100 mIU/mL ≥ concentrationS1 <1000 mIU/mL 19 157.7 236.0 0.3; 4322.0 17 (89%)
ConcentrationS1 ≥1000 mIU/mL 16 270.7 333.0 5.0; 8898.0 15 (94%)
ConcentrationS1=postbooster-dose concentration in initial study; ConcentrationPC=postchallenge-dose concentration 
(present study); GMC=geometric mean concentration; SPR=seroprotection rate (anti-HBs concentration ≥10 mIU/mL).
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immune memory mechanism. The exact dur- 
ation of protection is currently unknown, but in 
one effectiveness study in a country with high 
endemicity immunized subjects were reported 
to be protected for up to 18 years.26 However, 
in countries with lower endemicity, such as 
France and Italy, it is not known if subjects vac-
cinated during their infancy are protected to the 
same degree via this immune memory mech- 
anism, since, in high endemicity areas, it has 
been suggested that repeated exposure to wild-
type virus results in the boosting of immunity. 
In the studies reported here, in children fully 
immunized in infancy with a HBV-containing 
combination vaccine, and whose anti-HBs concen- 
trations had subsequently fallen below 10 mIU/mL 
at 4.5-6 years of age, we investigated HBsAg 
immune memory, as shown by the ability to 
mount an anti-HBs response. We observed that 
88.5% and 85.0% of the Hexavac- and Primavax-
primed children, respectively, mounted a sec-
ondary immune response when a challenge dose 
of monovalent HBV vaccine was used as a surro-
gate for exposure to wild-type HBV.
The children enrolled in these studies were 
a subset of the original study cohorts, and 
were selected because their anti-HBs concen-
trations had fallen below 10 mIU/mL in the 
antibody persistence study. All children with 
anti-HBs ≥10 mIU/mL after 5-6 years (42.1% 
with Hexavac; 55.4% with Primavax) would be 
predicted to have anti-HBs ≥10 mIU/mL after 
the challenge dose. Hence, the percentage of all 
children vaccinated in infancy with Hexavac or 
Primavax who remain protected against HBV in 
childhood, would have been higher than that 
observed in these studies, which included only 
those children who had become seronegative 
4.5-6.0 years after initial vaccination.
Our results demonstrate a secondary immune 
response to a challenge dose of HBV vaccine in 
children primed 6-7 years previously with an 
HBV-containing multivalent vaccine. A study 
conducted in a region in which HBV is endemic 
showed that the lack of a secondary immune 
response to a booster does not necessarily imply a 
lack of protection. Despite a correlation between 
protection from infection and initial response, 
none of the vaccinated children showing evid- 
ence of postvaccination HBV infection (anti-HBc 
positive) had a chronic infection, regardless of 
anti-HBs titers following the primary series.24 
Furthermore, a study in 76 healthcare workers 
who had failed to mount a humoral response 
to HBV vaccination found that 75% had devel-
oped specific cellular immune responses, which 
the investigators considered would protect them 
against viral infection.27
Several studies of long-term antibody persist-
ence following HBV vaccination and response 
to a booster dose have been performed in chil-
dren who were vaccinated at birth with a 
monovalent HBV vaccine.18,19,21,22 The major-
ity of these studies were performed in coun-
tries or populations of moderate or high HBV 
endemicity, where higher levels of natural 
exposure may influence the persistence of 
protection.17,28,29 Both the timing of the anti-
HBs testing and the specific definition of anam-
nestic response differed between studies, which 
showed a range of 89%-100% of HBV-vaccinated 
infants with anti-HBs titers ≥10 mIU/mL 
following a booster/challenge dose of mono- 
valent HBV vaccine. While the potential effects 
of the differences in methodology and setting 
cannot be ignored, these values are comparable 
with those seen in the current studies.
Recent studies have reported anti-HBs per-
sistence data for HBV-containing combination 
vaccines used according to European schedules 
and strong immune response after a booster 
vaccination.30-33 In one study, 79.6% of children 
primed with Hexavac at 2, 4, and 6 months of 
age had seroprotective anti-HBs titers prior to a 
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booster vaccination at 12-19 months of age.30 
One month following a booster dose of the hexa- 
valent DTaP-HBV-IPV/Hib vaccine, 98.1% had 
anti-HBs titers ≥10 mIU/mL. A substantial increase 
of anti-HBs concentration from prebooster to 
postbooster suggests that an anamnestic response 
was induced. Another analysis of anti-HBs per-
sistence in Italian children who received a pri-
mary series of either Hexavac or Infanrix at 3, 5, 
and 12 months of age found that seroprotection 
rates 12 months after the third dose were 69% 
and 96% respectively (relative risk 7.7; 95% CI 
3.1-18.9).31 One month after children with anti-
HBs titers <10 mIU/mL had received a booster 
dose of monovalent HBV vaccine corresponding 
to the recombinant HBV component included in 
the priming vaccine, five of five children primed 
with Infanrix and 24 of 26 Hexavac-primed chil-
dren were seroprotected, demonstrating persist-
ence of immune memory following priming with 
both hexavalent vaccines.31 As part of another 
Italian study, 342 children, who received a pri-
mary series of Engerix B at 3, 5, and 11 months 
of age had anti-HBs concentrations lower than 
10 mIU/mL or undetectable concentrations, more 
than 10 years later were given a booster vaccin- 
ation with Engerix.32 Two weeks after the booster 
97% (n=332) of the children had anti-HBs con-
centrations greater than 10 mIU/mL. Postbooster 
anti-HBs concentrations were higher in children 
whose prebooster concentrations were detectable 
but below 10 mIU/mL than in children whose 
concentrations were undetectable. In another two 
studies in Germany, children who had been vaccin- 
ated with four doses of Infanrix and whose anti-
HBs concentrations had fallen below 10 mIU/mL 
received one dose of Engerix B at 4-6 years old 
in one study and 7-9 years in the other.33 One 
month later the seroprotection rates were 88.5% 
and 95.1%, respectively. These response rates are 
comparable with those seen in the present studies 
in French and Italian children.
Our data do not allow us to assess the rel- 
ative effect of the vaccines used in the studies on 
the postchallenge results, either for the primary 
series and first booster or the challenge dose. 
Additionally, we cannot anticipate the level of 
protection of vaccinated nonresponders against 
clinical HBV infection and its clinical after- 
effects. Therefore, we are unable to judge whether 
similar results would have been obtained in an 
equivalent cohort who had been vaccinated 
10, 15, or 20 years earlier, or whether the per-
centage of nonresponders to a challenge dose 
of a HBV vaccine would have increased over 
time. Nevertheless, the present results confirm 
that the full primary vaccination schedule in 
infancy seems to confer long-term protection via 
immune memory and that an additional HBV 
dose is not generally required.
CONCLUSION
Analysis of responses to an HBV challenge 
in children vaccinated in infancy with an HBV-
containing combination vaccine, but whose 
anti-HBs concentrations had subsequently 
fallen below seroprotective levels, found that the 
majority mounted an anamnestic response to a 
challenge dose of monovalent HBV vaccine. In 
children who responded to the HBV component 
of Hexavac or Primavax in infancy (anti-HBs 
≥10 mIU/mL) and whose anti-HBs concen- 
trations subsequently fell below 10 mIU/mL by 
age 4.5-6 years, 88.5% and 85.0%, respectively, 
mounted an anamnestic response. If all children 
in the original cohorts, irrespective of their anti-
HBs antibody concentrations at age 4.5-6 years 
had been included in this challenge study, we 
can assume that the percentage of children who 
would have mounted an anamnestic response to 
the challenge dose would have been higher than 
that observed, since we can assume that all those 
children whose antibodies were ≥10 mIU/mL 
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at age 4.5-6 years would have responded. These 
results are consistent with those of other pub-
lished studies, despite differences in vaccines 
used, vaccination schedules, and HBV endemic-
ity in the study settings.
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